Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHADERM vs ALA-CORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Hypertension,Benign prostatic hyperplasia
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Hepatic via cytochrome P450 (CYP3A4); active metabolites.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; less than 10% metabolized hepatically.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Approximately 85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water.
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
Oral bioavailability is 70-80% due to first-pass metabolism; IM bioavailability is 90-95%.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
No dose adjustment required for renal impairment.
No adjustment required for topical use; systemic absorption minimal.
No dose adjustment required for hepatic impairment.
No adjustment required for topical use; hepatic metabolism negligible.
Safety and efficacy in pediatric patients have not been established.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
No specific dose adjustment; use with caution due to potential increased skin fragility.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
None.
None
Orthostatic hypotension and syncope, especially with first dose,May cause dizziness, drowsiness, or lightheadedness,Use caution in patients with hepatic impairment,May exacerbate angina or heart failure
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Hypersensitivity to alpha-blockers,History of orthostatic hypotension,Micturition syncope,Severe renal impairment,Concomitant use with PDE-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
No specific food interactions. However, high-fat meals may increase systemic absorption of topical tretinoin marginally; no dietary restrictions necessary. Avoid excessive vitamin A supplements to reduce risk of hypervitaminosis A.
No known food interactions with topical ALA-CORT.
Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fetal harm; avoid unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Unknown if excreted in human milk; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
Increased plasma volume may reduce drug levels; consider dose adjustment based on therapeutic drug monitoring. No specific dose adjustment established; use lowest effective dose.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
ALPHADERM (tretinoin 0.05% cream) is a retinoid used for photoaging and acne. Apply a pea-sized amount to dry skin 30 minutes after cleansing; avoid concomitant use of other topical retinoids or exfoliants to prevent irritation. Initiate therapy every other night to build tolerance. Strict sun protection required: use SPF 30+ daily. May cause initial flare of acne (retinoid 'purging') lasting 2-4 weeks. Contraindicated in pregnancy (FDA Category C).
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Apply a thin layer to affected areas once daily at bedtime, 30 minutes after washing and drying face.,Avoid excessive sun exposure; use broad-spectrum sunscreen and protective clothing.,Do not use with other medicated topical products, including benzoyl peroxide or salicylic acid.,Expect mild redness, peeling, or stinging initially; this usually subsides with continued use.,Notify your doctor if you are pregnant, planning pregnancy, or breastfeeding.,Store at room temperature away from heat and light.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHADERM vs ALA-CORT, answered by our medical review team.
ALPHADERM is a Topical Corticosteroid that works by Alpha-1 adrenergic receptor antagonist; blocks vasoconstriction and relaxes smooth muscle in blood vessels and prostate.. ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHADERM and ALA-CORT depend on the specific clinical indication. These are both Topical Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHADERM is: Topical: Apply a thin film to affected areas once daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHADERM and ALA-CORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHADERM is classified as Category C. Pregnancy Category C. First trimester: No adequate human studies; animal studies suggest embryocidal and teratogenic effects at high doses. Second/third trimester: Potential for fe. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.